(Q36393856)

13 August 2017

1 reference

title

Management of chronic hepatitis B virus infection: a new era of disease control (English)

1 reference

13 August 2017

1 reference

1 reference

1 reference

Farrell GC

1

1 reference

13 August 2017

Teoh NC

series ordinal

2

1 reference

13 August 2017

publication date

1 February 2006

1 reference

Internal Medicine Journal

13 August 2017

published in

1 reference

13 August 2017

volume

36

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

100-113

1 reference

Management of chronic hepatitis C virus infection: a new era of disease control

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Hepatitis B e antigen and the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Hepatitis B virus infection--natural history and clinical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Therapeutic advances in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Hepatitis B viral resistance: mechanisms and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Natural history of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Varied assembly and RNA editing efficiencies between genotypes I and II hepatitis D virus and their implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Liver transplantation in patients with HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Lamivudine in hepatitis B-associated membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Remission of hepatitis B virus-related vasculitis with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Asian-Pacific consensus statement on the management of chronic hepatitis B: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Durability of serologic response after lamivudine treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Clinical trial results of new therapies for HBV: implications for treatment guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Treatment of chronic hepatitis B in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2006.01027.X

10.1111/J.1445-5994.2006.01027.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference